The Consistency Breakthrough
in EV Therapeutics

FT-01: A scalable platform for reliable, clinical-grade extracellular vesicles

Solving the Critical Bottleneck

Traditional EV production has relied on variable primary donor cells, creating an inconsistent source that yields inconsistent EV products. This fundamental challenge has prevented EV therapies from reaching their clinical and commercial potential.

FT-01 represents a paradigm shift: our proprietary, immortalised mesenchymal stem cell line provides an inexhaustible supply of bioactive EVs with consistent characteristics. This breakthrough combines the therapeutic benefits of cell-based treatments with pharmaceutical-grade reproducibility and superior safety profiles.

Platform Technology Deep Dive

FT-01 was developed through decades of expertise in mesenchymal stem cells and extracellular vesicles. Our research journey identified and developed the ideal MSC clone through rigorous scientific evaluation, resulting in unique advantages that set our platform apart.

Scientific Foundation

Every FT-01 cell shares identical genetic characteristics, ensuring that EVs produced across different batches maintain consistent therapeutic properties. This eliminates the donor-to-donor variability that has plagued traditional EV production methods.

Immortalised Cell Line

Unlike primary cells that age and change over time, FT-01 maintains stable characteristics through extensive passaging, providing an inexhaustible source for large-scale production.

Comprehensive EV Characterisation

Our comprehensive characterisation includes extensive biophysical analysis and cargo profiling, ensuring that FT-01 EVs maintain consistent therapeutic properties including growth factors, cytokines, and regulatory molecules that drive tissue repair and immune modulation.

Clonal Cell Line Technology

Manufacturing Excellence

A modern laboratory with glass walls and stainless steel tables, equipped with scientific instruments, computers, and laboratory equipment.

Breakthrough Scalability

FT-01 has demonstrated remarkable scalability, achieving an 84% reduction in the cost of goods while maintaining product quality. This breakthrough makes clinical-grade EV production economically viable for widespread therapeutic application.

    • Scalable from pilot to commercial production volumes

    • Consistent yield and quality across production runs

    • Standard bioreactor compatibility for established manufacturing infrastructure

    • Reduced raw material costs compared to donor-dependent processes

  • Our platform incorporates GMP-ready processes and quality controls, ensuring regulatory compliance and product consistency. This includes comprehensive characterisation methods, stability protocols, and release testing procedures.

Therapeutic Applications

Microscopic image of a cell stained with fluorescent dyes showing the cell's structure, including blue nuclei, red cytoskeleton, and green highlights.

Versatile Platform for Diverse Applications

FT-01 has demonstrated remarkable scalability, achieving an 84% reduction in the cost of goods while maintaining product quality. This breakthrough makes clinical-grade EV production economically viable for widespread therapeutic application.

    • Unmodified FT-01 EVs harness the natural therapeutic properties of mesenchymal stem cells, offering applications in:

      • Autoimmune and inflammatory conditions

      • Tissue regeneration and wound healing

      • Neurodegenerative diseases

      • Cardiovascular disorders

  • FT-01 EVs can be engineered with tissue-specific targeting capabilities, enabling precise delivery to:

    • Tumor microenvironments for oncology applications

    • Central nervous system for neurological disorders

    • Specific inflammatory sites for localised treatment

  • Our platform enables loading of FT-01 EVs with bespoke therapeutic cargo:

    • RNA molecules for gene regulation

    • Therapeutic proteins for targeted biological activity

    • Small molecule drugs for targeted delivery

    • Combination therapies for complex multi-pathway diseases

Partnership and Licensing

A group of scientists in a laboratory, with one scientist looking through a microscope and others working around him.

Accelerating EV Innovation Through Collaboration

FT-01 offers partners a complete solution for EV therapeutic development, eliminating the years typically required to establish consistent production capabilities. Our platform reduces development timelines while significantly lowering manufacturing and regulatory risk.

    • Platform Licensing: Complete access to FT-01 technology for specific therapeutic applications

    • Joint Development: Collaborative research programs in areas of mutual interest

    • Manufacturing Services: Production of GMP-grade EVs using our established platform

    • Technical Support: Knowledge transfer and ongoing scientific collaboration

  • Our strong alignment with key opinion leaders including Versus Arthritis, University of York, and world-class advisory board members supports the scientific credibility and commercial potential of our platform.

Discuss Collaboration Opportunities

Learn more